Can Biosimilars Reduce Specialty Spending?

David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.

Related Content:

InterviewsBiosimilarsSpecialty Pharmacy

Addressing Logistical Challenges of CAR T Therapy Administration in Inpatient, Outpatient Settings

Five Key Things Pharmacists Need to Know As Insulin Biosimilars Come to Market

FDA Approves Insulin Glargine-yfgn as First Interchangeable Biosimilar Insulin Product for Diabetes